Research and Clinical Trials

Title  

TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Brief Description  

- To evaluate the safety and tolerability of TSR-042 using Common Terminology Criteria for Adverse Events (CTCAE v.4.03) in patients with advanced solid tumors - To evaluate the antitumor activity of TSR-042 in patients with advanced solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Ovary

Status  

OPEN

Start Date  

07/05/2017

IRB Number  

00021131

Principal Investigator  

Brown, Jubilee

Contact Name  

Mandy Campbell

For More Information, Contact  Mandy  , Campbell
Phone:  980-442-2340 Fax:    
Email:  Amanda.Setzer@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204